Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366494 · ClinicalTrials.gov registry record
Micro RNAs to Predict Response to Androgen Deprivation Therapy
A clinical trial of Prostate Cancer, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT02366494: Completed study of Prostate Cancer, sponsored by Medical College of Wisconsin.
NCT02366494 is a study of Prostate Cancer that has completed, run by Medical College of Wisconsin. The registered enrollment target is 42 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02366494, a study of Prostate Cancer, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Identify exosomal micro RNA that predict responses to ADT
Primary Outcome
Two hundred to 300 microRNAs will be identified by RNA sequencing. This outcome measure will report the read count per million of the top-five most prevalent microRNAs that correlate with responses.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Goserelin
- DRUG Bicalutamide
- DRUG Leuprolide
- DRUG Triptorelin
Study Locations (1)
Wisconsin
- Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-04-29 |
| Est. Completion | 2021-05-11 |
What the finished NCT02366494 record still lists
NCT02366494 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT02366494 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02366494 about?
NCT02366494 is a clinical study titled "Micro RNAs to Predict Response to Androgen Deprivation Therapy". Identify exosomal micro RNA that predict responses to ADT
What is the current status of trial NCT02366494?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2015-04-29. Estimated completion is 2021-05-11.
What conditions does trial NCT02366494 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02366494?
The interventions under investigation include: Docetaxel (DRUG), Goserelin (DRUG), Bicalutamide (DRUG), Leuprolide (DRUG), Triptorelin (DRUG).
Who is sponsoring clinical trial NCT02366494?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366494 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02366494's enrollment target sits among peer trials
42 520th of 735 higher than 212 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI